The Global Oropharyngeal Cancer Market Will Grow At Highest Pace Owing To Rising Technological Advancements For Early Diagnosis

By Author: Ravina Pandya
Total Articles: 28
Comment this article

Oropharyngeal cancer refers to cancers that develop in the oropharynx, which is the middle part of the throat located between the nasal cavity and the larynx. It includes cancers of the base of the tongue, tonsils, soft palate, and sides and back of the throat. The exact origins of oral cancers are often difficult to determine and may involve a combination of risk factors like smoking, chewing tobacco, heavy alcohol use, HPV infection, and genetic factors. Early symptoms include a sore throat that does not go away, a lump in the neck, difficulty swallowing, and ear pain. Treatment options comprise surgery, radiation therapy, chemotherapy, targeted therapy and immunotherapy based on the stage of cancer.

The oropharyngeal cancer market is estimated to be valued at USD 2.11 Bn in 2024 and is expected to reach USD 3.05 Bn by 2031, growing at a compound annual growth rate (CAGR) of 5.4% from 2024 to 2031.

Key players operating in the oropharyngeal cancer market are Bristol-Myers Squibb, Merck, Pfizer, AstraZeneca, Eli Lilly and Company, F. Hoffmann-La Roche Ltd., and Novartis AG.

Key Takeaways

Key players: ...
... Key players operating in the oropharyngeal cancer market are Bristol-Myers Squibb, Merck, Pfizer, AstraZeneca, Eli Lilly and Company, F. Hoffmann-La Roche Ltd., and Novartis AG. These players are mainly focused on developing new drugs and combination therapies for better treatment outcomes.

Growing demand: Rising prevalence of HPV-related Oropharyngeal Cancer Market globally is a major factor driving the market growth. According to the National Cancer Institute, around 13,170 new cases of oropharyngeal cancer are expected to be diagnosed in 2022 in the United States.

Technological advancement: Developments in diagnostic techniques such as PET scans and MRI for early detection of cancer are also fueling the market expansion. In addition, growing research in immunotherapy and targeted drug therapies is further supporting the market growth.

Market Trends

Increasing combination therapy: There is a growing trend of using combination therapies involving chemotherapy, radiation, targeted drugs and immunotherapy to enhance treatment efficacy. Combination approaches help to achieve better response rates.

Focus on biomarker development: Companies are investing heavily in research studying biomarkers that can help in patient selection for specific therapies. Identification of biomarkers helps design personalized treatment approaches.

Market Opportunities

Developing economies: Emerging countries in Asia Pacific and Latin America present significant opportunities for market players due to growing patient pool, rising healthcare spending and increasing awareness about cancer.

Immunotherapy drugs: With greater understanding of cancer immunology, immunotherapy drugs hold promising growth prospects. Several immunotherapies are under clinical trials for oropharyngeal cancer treatment.

Impact of COVID-19 on Oropharyngeal Cancer Market Growth

The COVID-19 pandemic had a significant impact on the growth of the oropharyngeal cancer market globally. During the initial stages of the pandemic, when lockdowns were imposed worldwide, the number of new cancer cases detected declined sharply as people avoided in-person visits to hospitals and clinics. Cancer screening and routine check-ups were postponed or cancelled which led to delayed cancer diagnosis. Furthermore, the focus of healthcare resources shifted towards managing the rising COVID-19 caseload which disrupted the supply of cancer drugs and therapies. All these factors negatively impacted the growth of the oropharyngeal cancer market in 2020.

However, as vaccination drives progressed and lockdowns were gradually lifted in 2021, the market saw a revival. The number of cancer screenings and new patient visits to oncologists increased. While the pandemic continued to strain healthcare systems, focus was regained on cancer treatment. Telehealth also emerged as an important medium for cancer consultations and management of stable patients. Drug manufacturers ramped up production to meet the resurging demand. Researchers assessing the long-term impact of delays in cancer diagnosis and treatment anticipate that the oropharyngeal cancer market may experience above average growth in the coming years to make up for the cases that went undetected during the peak pandemic period. Further advances in diagnosis and treatment modalities will be the key to future growth.

Geographical Regions with Highest Market Value

North America region accounts for the largest share of the global oropharyngeal cancer market in terms of value. This is attributed to factors like availability of advanced diagnostic facilities, presence of prominent pharmaceutical companies, favorable reimbursement policies, and growing public awareness about oral cancers in countries like the United States. The region is anticipated to retain its leading position over the forecast period driven by continuous technological innovations and new product launches for screening, diagnosis and treatment of oropharyngeal cancer.

Fastest Growing Regional Market

The Asia Pacific region is projected to register the highest growth in the oropharyngeal cancer market during 2022-2028. Rising geriatric population afflicted by the disease along with growing healthcare expenditure is fueling the market growth in Asia Pacific countries including China, India and Japan. Increasing focus of international players on emerging APAC economies through partnerships with local healthcare providers will further support the fast pace of growth of the oropharyngeal cancer market in this region.

Get More Insights on- Oropharyngeal Cancer Market

About Author:

Ravina Pandya, Content Writer, has a strong foothold in the market research industry. She specializes in writing well-researched articles from different industries, including food and beverages, information and technology, healthcare, chemical and materials, etc.

(https://www.linkedin.com/in/ravina-pandya-1a3984191)